Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.
A New York fertility doctor accuses Repros CEO of stealing the idea for a new oral testosterone therapy.
Fish oil supplements have no heart benefits for patients, which doesn't bode well for Amarin's efforts to market Vascepa.
Osiris CEO claims Prochymal is most widely used stem cell drug in world yet has generated no sales -- ever.
DEA finalizes Belviq abuse schedule, allowing the weight-loss pill launch in June.
Heads need to roll at Aveo because of the FDA's thrashing of the company's kidney cancer drug.
This group of contestants have nearly perfect records picking FDA and European drug approvals.
Join TheStreet's Adam Feuerstein as he live blogs FDA advisory panels for Aveo Oncology and Delcath Systems
Hemispherx CEO earns a bonus for overseeing the sale of company stock.